The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance  by Lee, Changhan et al.
ArticleThe Mitochondrial-Derived Peptide MOTS-c
Promotes Metabolic Homeostasis and Reduces
Obesity and Insulin ResistanceGraphical AbstractHighlightsd MOTS-c is a 16-amino-acid peptide encoded in the
mitochondrial genome
d MOTS-c targets muscle and regulates metabolism via the
folate-purine-AMPK pathway
d MOTS-c mediates mitochondrial regulation of insulin and
metabolic homeostasis
d MOTS-c protects against age- and diet-dependent insulin
resistance and obesityLee et al., 2015, Cell Metabolism 21, 443–454
March 3, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cmet.2015.02.009Authors
Changhan Lee, Jennifer Zeng, ...,
Rafael de Cabo, Pinchas Cohen
Correspondence
changhan.lee@usc.edu (C.L.),
hassy@usc.edu (P.C.)
In Brief
Lee et al. identify a novel bioactive
mitochondrial-derived peptide (MOTS-c)
encoded in the mitochondrial DNA that
regulates metabolic homeostasis. MOTS-
c regulates insulin sensitivity and
metabolic homeostasis via AMPK, and
prevents age-dependent and high-fat-
diet-induced insulin resistance, as well as
diet-induced obesity.
Cell Metabolism
ArticleThe Mitochondrial-Derived Peptide MOTS-c
Promotes Metabolic Homeostasis
and Reduces Obesity and Insulin Resistance
Changhan Lee,1,* Jennifer Zeng,1 Brian G. Drew,2 Tamer Sallam,4 Alejandro Martin-Montalvo,3 Junxiang Wan,1
Su-Jeong Kim,1 Hemal Mehta,1 Andrea L. Hevener,2 Rafael de Cabo,3 and Pinchas Cohen1,*
1Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA
2Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles,
CA 90095, USA
3Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA
4Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
*Correspondence: changhan.lee@usc.edu (C.L.), hassy@usc.edu (P.C.)
http://dx.doi.org/10.1016/j.cmet.2015.02.009SUMMARY
Mitochondria are known to be functional organelles,
but their role as a signaling unit is increasingly being
appreciated. The identification of a short open read-
ing frame (sORF) in the mitochondrial DNA (mtDNA)
that encodes a signaling peptide, humanin, suggests
the possible existence of additional sORFs in the
mtDNA. Here we report a sORF within the mitochon-
drial 12S rRNA encoding a 16-amino-acid peptide
named MOTS-c (mitochondrial open reading frame
of the 12S rRNA-c) that regulates insulin sensitivity
and metabolic homeostasis. Its primary target organ
appears to be the skeletal muscle, and its cellular ac-
tions inhibit the folate cycle and its tethered de novo
purine biosynthesis, leading to AMPK activation.
MOTS-c treatment inmice prevented age-dependent
and high-fat-diet-induced insulin resistance, as well
as diet-induced obesity. These results suggest that
mitochondria may actively regulate metabolic ho-
meostasis at the cellular and organismal level via
peptides encoded within their genome.
INTRODUCTION
Themitochondrion is largely viewed as a utilitarian organelle that
provides various services to the cell, chiefly metabolism and
energy production. The regulation of these pathways is often
described to occur through vertical, rather than horizontal,
communication where mitochondria are at the receiving end.
Nonetheless, mitochondria also relay information via several
known retrograde signaling molecules, such as reactive oxygen
species (ROS), Ca2+, and cytochrome C (Goodwin et al., 2009;
Houtkooper et al., 2011; Sethe et al., 2006). For instance,
numerous studies suggest that mitochondrial ROS have evolved
as a key communication method between the mitochondria and
the cell to regulate homeostasis and normal cellular function
(Sena and Chandel, 2012). Although essential, these are not of
mitochondrial origin, but are secondary metabolites, transientCemolecules, or nuclear-encoded proteins that reside in the mito-
chondria. Recent reports provide further evidence of mitochon-
drial signals transmitted as part of the mitochondrial unfolded
protein response (mtUPR) that regulate critical processes such
as aging, inflammation, and stress resistance (Durieux et al.,
2011; Lee et al., 2013; Long et al., 2014; Nakahira et al., 2011;
Yun and Finkel, 2014). Yet, humanin is currently the only reported
mitochondrial-derived peptide (MDP) whose short open reading
frame (sORF) maps to the mitochondrial DNA (mtDNA) (Guo
et al., 2003; Hashimoto et al., 2001; Ikonen et al., 2003; Lee
et al., 2013).
The mitochondrial genome is traditionally described as a
compact circular genetic system that encodes 13 proteins dedi-
cated to energy production. Relatively little is understood of its
unique genetic system that reflects its bacterial ancestry. The
mitochondrial transcriptome, once considered relatively simple,
is in fact a highly complex systemwith previously unknown char-
acteristics including small RNAs encoded by the mtDNA (Mercer
et al., 2011). Following on the identification of humanin, we set
out to identify additional sORFs in the mtDNA. Notably, sORFs
have recently been actively investigated in the nuclear genomes
of Drosophila (Galindo et al., 2007; Kondo et al., 2010; Magny
et al., 2013; Savard et al., 2006) and mammals (Frith et al.,
2006; Slavoff et al., 2013), largely owing to technological ad-
vances that enable their detection and analysis. Here, we des-
cribe the identity of a sORF encoded within the mitochondrial
12S rRNA that yields a bioactive peptide involved in regulating
metabolic homeostasis.
RESULTS
Identification of a Novel Expressed sORF Encoded
within the Mitochondrial Genome
Previously, cDNAs mapping to the 12S rRNA region have been
cloned from humanmyeloblasts after stimulation with interferon,
but the exact sequences have not been identified (Tsuzuki et al.,
1983). An in silico search for potential sORFs within the human
12S rRNA revealed one consisting of 51 base pairs with a strong
Kozak sequence (Harhay et al., 2005) that translates into a 16-
amino-acid peptide subject to several putative post-translation
modifications (Figures 1A, S1A, and S1B). We have named this
peptide MOTS-c (mitochondrial open reading frame of the 12Sll Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc. 443
Figure 1. Identification of a Novel Expressed sORF Encoded within the Mitochondrial Genome
(A) MOTSC is encoded as a 51-bp short open reading frame (sORF) in the mitochondrial 12S rRNA. The mitochondrial genetic code yields tandem start/stop
codons, whereas the cytoplasmic genetic code yields a viable peptide.
(B) 30 rapid amplification of cDNA ends (30 RACE) of polyadenylated MOTS-c and humanin transcripts.
(C–E) Phylogenetic analysis of MOTS-c with (C) multiple peptide sequence alignment in 14 species, (D) its phylogenetic tree and branch length (estimated
number of substitutions per site), (E) the rate of non-synonymous (dN) and synonymous (dS) substitutions, and their ratio (dN/dS) for the first well-conserved
11 residues of MOTS-c. The red bars represent residues that evolved under significant positive selection, and the gray bars represent those under significant
purifying selection.
(F–H) HeLa-r0 cells are devoid of mitochondrial DNA. HeLa cells versus HeLa-r0 La cells: (F) 12S rRNA and MOTS-c transcripts by qRT-PCR, (G) MOTS-c
peptide and mitochondrial-encoded cytochrome C oxidase I and II (MT-COI/II) protein, and nuclear-encoded GAPDH by immunoblotting, (H) MOTS-c (green),
mitochondrial resident HSP60 (red), and nucleus (blue) by immunocytochemistry (ICC). Scale bar, 100 mm.
(I) MOTS-c (green), HSP60 (red), and nucleus (blue) immunostaining in HEK293 cells. Scale bar, 20 mm.
(J) Time-course detection of MOTS-c and MT-COI after treating with actinonin (150 mM), which causes mitochondrial RNA degradation.
(K and L) MOTS-c is detected in (K) various tissues in mice and rats and (L) circulation (plasma) in humans and rodents.
(M and N) Fasting alters expression of endogenous MOTS-c in (M) tissues and (N) plasma in mice. Data shown as mean ± SEM. Student’s t test. *p < 0.05,
**p < 0.01, ***p < 0.001. See also Figure S1 and Table S1 for additional information on MOTS-c and validation for Western blotting, ICC, and ELISA.rRNA type-c). MOTS-c peptide translation obligatorily occurs in
the cytoplasm using the standard genetic code because mito-
chondrial translation, using the mitochondria-specific genetic
code, yields tandem start and stop codons (Figure 1A). This sug-
gests that its polyadenylated transcript (Figure 1B) is exported
from the mitochondria. Mitochondrial RNAs, both tRNA and
rRNA, are exported out of the mitochondria via mechanisms
that are still poorly understood (Amikura et al., 2001; Attardi
and Attardi, 1968; Kashikawa et al., 1999, 2001; Kobayashi
et al., 1993, 1998; Maniataki and Mourelatos, 2005; Nakamura
et al., 1996). Multiple peptide sequence alignment of 14 species444 Cell Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc.and its deduced phylogenetic tree suggest thatMOTS-c is highly
conserved, especially the first 11 residues (Figures 1C and 1D).
To test if these 11 amino acids evolved over positive selection,
we calculated ratios of non-synonymous (dN) to synonymous
substitutions (dS), and their rate (dN/dS) for each residue in 14
species. We found that four residues were significantly undergo-
ing positive selection (dN/dS > 1) at positions 4 (Q), 5 (E), 7 (G),
and 9 (I), and two residues were undergoing purifying selection
(dN/dS < 1) at positions 3 (W) and 10 (F) (Figure 1E). Positive se-
lection was also detected by random effects likelihood (REL)
analysis implemented in the HyPhy package with posterior
probability greater than 0.95 and Bayes factor greater than
50 (Figure S1C) (Kosakovsky Pond and Frost, 2005). All
further studies were performed based on the human MOTS-c
sequence.
We recognized the possibility that MOTS-c could also be of
nuclear origin due to a phenomenon known as nuclear mtDNA
transfer (NUMT) (Ricchetti et al., 2004). Using the NCBI nucleo-
tide basic local alignment search tool (BLASTN 2.2.29+) (Altschul
et al., 1997), we found that none of the putative NUMT-derived
peptides shared complete homology with mitochondrial-en-
coded MOTS-c (Figure S1D). Furthermore, a BLAST search
using the human expression sequence tag (EST) database re-
vealed 101 hits whose mRNA sequences were all completely
homologous to the mitochondrial 12S rRNA locus (Table S1).
Interestingly, rats (Rattus norvegicus) do not have any NUMT se-
quences for MOTS-c, making mtDNA its exclusive source.
Because of the lack of methods for targeted knockout or knock-
down of mitochondrial genes, to further confirm itsmitochondrial
origin in humans, we selectively depleted mtDNA in HeLa cells
(HeLa-r0)(Hashiguchi and Zhang-Akiyama, 2009) and show
the elimination of both 12S rRNA and MOTS-c transcripts (Fig-
ure 1F). HeLa-r0 cells had undetectable levels of mitochon-
drial-encoded cytochrome oxidase I and II (MT-COI/II) and
MOTS-c, measured using specific MOTS-c antibodies (Fig-
ure S1E), whereas nuclear-encoded GAPDH expression was
unaltered (Figure 1G). HeLa and HEK293 cells showed a certain
degree ofmitochondrial co-localization (Figures 1H, 1I, and S1F);
HeLa-r0 cells showed loss of MOTS-c expression and mito-
chondrial co-localization (Figure 1H). Furthermore, we also
selectively depleted mitochondrial RNA using actinonin (Richter
et al., 2013), and show loss of MOTS-c and MT-COI expression
in a time-dependent manner (Figures 1J and S1H). Therefore,
using the r0 system and actinonin, we provide evidence of mito-
chondrial origin for MOTS-c at the DNA and RNA level, respec-
tively. MOTS-c was detected in various tissues in mice and
rats (Figure 1K) as well as in circulation in human and rodent
plasma as determined with a MOTS-c-specific ELISA (Figures
1L, S1G, and S1H); again, NUMTs are absent in the rat, making
the mtDNA the only possible source of MOTS-c. Notably, fasting
lowered endogenous expression of MOTS-c in certain metabol-
ically active and mitochondria-rich tissues (skeletal muscle and
testes) as well as in plasma, whereas homeostatic tissues
(such as brain and heart) showed sustained levels (Figures 1M
and 1N).
MOTS-c Is a Bioactive Peptide that Regulates Gene
Expression and Cellular Metabolism
Microarray analyses performed on HEK293 cells treated with
MOTS-c for 4 and 72 hr indicated that MOTS-c is a biologically
active peptide (Figures 2A–2D). Principal component analysis
(PCA) showed a clear global gene expression profile shift by
72 hr after MOTS-c treatment (Figure 2A). To further highlight dif-
ferences between functional pathways modified by MOTS-c, we
employed parametric analysis of gene set enrichment (PAGE) to
show that gene expression was significantly altered by 4 hr after
MOTS-c treatment, which became remarkably distinct by 72 hr
(Figure 2B). There was only a modest overlap between gene sig-
natures at 4 and 72 hr, suggesting a time-dependent progression
in response to MOTS-c treatment (Figure 2C). Notably, MOTS-cCehad a marked effect on expression of genes associated with
cellular metabolism and inflammation (Figure 2D; Table S2).
Since the central function of mitochondria involves metabolic
processes, we next examined the effect of MOTS-c on cellular
metabolism using unbiased global metabolomic profiling
in vitro with a ‘‘gain-of-function’’ model using HEK293 cells either
stably overexpressing MOTS-c (MOTS-c-ST) or treated exoge-
nously with synthetic MOTS-c (10 mM) for 24 and 72 hr. Of the
356 named metabolites, 194 were significantly altered in
MOTS-c-ST cells, and 49 and 177 were significantly altered after
24 and 72 hr, respectively (Figure 2E). The pattern of metabolites
also progressed with time, and most biochemicals remained
consistently altered both at 24 and 72 hr (Figure 2F). Themajority
of metabolites altered inMOTS-c-ST cells overlapped with those
in cells treatedwithMOTS-c for 72 hr (Figure 2F). Therewereme-
tabolites that were consistently changed in all three groups;
those involved in purine metabolism and dipeptide metabolism
were consistently reduced, whereas those involved in acylcarni-
tine metabolism and the methionine cycle were significantly
increased (Figure 2G).
MOTS-c Targets theMethionine-FolateCycle, Increases
AICAR Levels, and Activates AMPK
We identified a distinct metabolic signature from our global unbi-
asedmetabolomic profiling inMOTS-c-ST cells that strongly sug-
gested its target of action as the folate-methionine cycle and the
directly tethereddenovopurinebiosynthesis pathway (Figure 3A).
We overlaid our microarray analysis with our metabolomics
profiling and found that MOTS-c altered gene expression of en-
zymes involved in the folate-methionine cycle and de novo purine
synthesis as early as 4 hr post-treatment (Figures 3A and 3B). We
observed a concerted decrease in the levels of 5-methyl-tetrahy-
drofolate (5Me-THF), the most abundant form of activated folate,
and methionine, and elevated levels of homocysteine inMOTS-c-
ST cells (Figures 3A and 3C). Notably, 5Me-THF levels declined
prior to changes in methionine-homocysteine in HEK293 cells
treated exogenously with MOTS-c, suggesting the regulation of
the folate cycle occurs earlier (Figure S2A). Also, as expected,
5Me-THF depletion was coupled with the blockade of de novo
purine biosynthesis (Figures 3A and 3D), resulting in an accumu-
lation of endogenous AICAR (5-aminoimidazole-4-carboxamide
ribonucleotide) to levels higher than 20-fold in MOTS-c-ST cells
compared to control cells (Figures 3A and 3E), causing an ex-
pected significant decrease in purines (Chan and Cronstein,
2010); this was also observed, but to a lesser extent, 72 hr after
exogenous MOTS-c treatment (Figure S2B). Because de novo
purine synthesis is feedback-regulated by purine products, our
data suggest accelerated de novo purine synthesis in MOTS-c-
ST cells indicated by increased levels of its precursor metabolites
NAD+, glycolysis, and the pentose phosphate pathway (PPP), as
discussed below, simultaneously with reduced levels of ADP-
ribose and R5P (Figures 3A, 3D, and S2C).
A well-described role of AICAR is to activate AMPK and
stimulate fatty acid oxidation via phosphorylation-induced inac-
tivation of acetyl-CoA carboxylase (ACC) that consequently alle-
viates allosteric inhibition of carnitine palmitoyltransferase 1
(CPT-1), and also enhance glucose uptake in muscle (Steinberg
and Kemp, 2009). MOTS-c treatment led to the phosphory-
lation of AMPKa (Thr172) and Akt (Ser473) in a time- andll Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc. 445
Figure 2. MOTS-c Is a Bioactive Peptide that Regulates Gene Expression and Cellular Metabolism
(A–D) Microarray analyses on HEK293 cells treated with MOTS-c (10 mM) for 4 and 72 hr (n = 6).
(A) Principal component analysis (PCA).
(B) Parametric analysis of gene set enrichment (PAGE) relative to control cells at the same time point.
(C) Venn diagram depicting upregulated (red) and downregulated (blue) genes per time point.
(D) Gene ontology analysis on HEK293 cells treated with MOTS-c for 72 hr.
(E–G) Global unbiased metabolomics on HEK293 cells treated with MOTS-c (10 mM) for 24 and 72 hr or stably transfected with MOTS-c (MOTS-c-ST) or empty
vector (EV-ST) (n = 5). Welch’s two sample t test.
(E) Total number of significantly or near-significantly changed metabolites.
(F) Venn diagram depicting upregulated (red) and downregulated (blue) metabolites in MOTS-c-ST cells and HEK293 cells treated with MOTS-c for 24 and 72 hr
compared to their controls.
(G) List of metabolites that were consistently altered in all three groups. See also Table S2.dose-dependent manner (Figure 3F). Further, after 72 hr of
MOTS-c treatment, increased phosphorylation of AMPKa2
(Thr172) and ACC (Ser79), and elevated CPT-1 protein levels,
were detected (Figure 3G). Notably, AMPK activation occurred
despite lower AMP levels and higher ADP and ATP levels (Fig-
ure S2D) similar to that achieved by salicylate (Hashiguchi and
Zhang-Akiyama, 2009), leptin (Ohta et al., 2009), and metformin
(Fujii et al., 2006). Consistent with this notion, the folate cycle,
specifically 5Me-THF, has recently been shown to be a target
of the AMPK-activating drug metformin (Cabreiro et al., 2013;446 Cell Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc.Corominas-Faja et al., 2012). We also confirmed elevated levels
of MOTS-c and phosphorylation of AMPKa2 (Thr172) in MOTS-
c-ST cells (Figure 3H).
We next investigated the effect of MOTS-c on relevant cellular
metabolism including glycolysis, mitochondrial function, and
fatty acid oxidation. MOTS-c appeared to stimulate glucose uti-
lization evidenced by increased glucose clearance and lactate
accumulation in culture media (Figures 4A, 4B, and S3A–S3C)
coupled with decreased intracellular glucose levels, along with
other glycolytic intermediates (Figure 4C). Similar findings were
Figure 3. MOTS-c Targets the Methionine-Folate Cycle, Increases AICAR Levels, and Activates AMPK
(A and B) The effect of ‘‘gain-of-function’’ of MOTS-c on the folate-methionine cycle and de novo purine biosynthesis in MOTS-c-ST cells.
(A) Metabolites were measured by mass spectrometry (n = 5).
(B) Enzymes altered 4 hr after MOTS-c treatment were determined by microarray (n = 6). GART, phosphoribosylglycinamide formyltransferase (a trifunctional
enzyme); ATIC, AICAR transformylase IMP carboxylase (a bifunctional enzyme); MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; MTRR, MTR
reductase; 5Me-THF, 5-methyl-tetrahydrofolate; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide.
(C) 5Me-THF and the methionine cycle intermediates in MOTS-c-ST cells (n = 5).
(D) Metabolic intermediates of the de novo purine biosynthesis pathway in MOTS-c-ST cells (n = 5).
(E) AICAR levels in MOTS-c-ST cells measured by mass spectrometry (n = 5).
(F) MOTS-c promotes AMPK (Thr172) and Akt (Ser473) phosphorylation in a time- and dose-dependent manner in HEK293 cells.
(G) AMPK phosphorylation and its downstream pathways that control fatty acid oxidation (ACC andCPT-1) 72 hr after MOTS-c treatment (10 mM) in HEK293 cells.
(H) MOTS-c-ST cells have higher levels of MOTS-c and phosphorylation of AMPK, but no changes in MT-COI, SIRT1, and GAPDH levels. Data shown as mean ±
SEM. Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2 for data on exogenous MOTS-c treatment and NAD+/NADH and adenine derivatives.observed in HEK293 cells within 24 hr of MOTS-c treatment (Fig-
ure S3D). Notably, our data suggest increased routing of glucose
to the PPP, the anabolic branch of glycolysis that provides
ribose-5-phosphate as a precursor for de novo purine synthesis,
as indicated by reduced intermediates leading to the accumula-
tion of AICAR in MOTS-c-ST cells and also in HEK293 cells after
exogenous MOTS-c treatment (Figures 4C and S3D). To directly
test glycolytic flux in real time, we measured extracellular acidi-
fication rate (ECAR). Upon glucose stimulation MOTS-c-ST cells
showed significantly enhanced glycolytic response, reaching
maximum glycolytic capacity only typically achieved after oligo-
mycin treatment (Figure 4D). Because MOTS-c targets the folate
cycle and depletes intracellular 5Me-THF levels, we were able to
reverse the enhanced glycolytic response inMOTS-c-ST cells byCesupplementing the culture media with folic acid (100 nM) (Fig-
ure 4D); similar results were observed in HEK293 treated with
MOTS-c (Figure S3E). To confirm the specificity of the MOTS-c
sequence, we substituted two highly conserved residues to
alanine and created null mutants that did not show enhanced
glycolytic response to glucose stimulation in HEK293 cells.
Thesemutants were glutamic acid in position 5 (E5A) and glycine
in position 7 (G7A) (Figure S3F). Furthermore, we generated a
randomly scrambled MOTS-c peptide sequence that did not
have any primary sequence homology to known peptides/pro-
teins (M3S1) and showed lack of enhanced glycolytic response
to glucose stimulation in HEK293 cells (Figure S3G).
Because treating and overexpressing MOTS-c increased
AMPK activity (p-Thr172-AMPKa2), we tested the requirementll Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc. 447
Figure 4. MOTS-c Coordinates Cellular Glucose, Mitochondrial, and Fatty Acid Metabolism
(A and B) Extracellular (A) glucose and (B) lactate in the culture medium of MOTS-c-ST cells (n = 6).
(C) Intracellular metabolites of glycolysis and the pentose phosphate pathway (PPP) in MOTS-c-ST cells (n = 5). Cells were seeded and allowed to acclimate for
72 hr prior to collection, at which time they were 90%–95% confluent.
(D) Real-time glycolytic flux determined by extracellular acidification rate (ECAR) in MOTS-c-ST cells treated with folic acid (100 nM) for 72 hr (n = 6).
(E–H) Glucose-stimulated real-time glycolytic measurements in MOTS-c-ST cells treated with (E) siRNA against AMPKa2 (48 hr), (F) siRNA against AMPKa1/2
(48 hr), or (G) compound C (10 mM) (24 hr) and (H) the relative percent changes of ECAR of each treated group to their corresponding controls in (E)–(G).
(I) Real-time oxygen consumption rate (OCR) in MOTS-c-ST cells treated with folic acid (100 nM) for 72 hr (n = 6). All values normalized against DNA content.
(J) MOTS-c-ST cell proliferation after 72 hr under equimolar (25 mM) glucose or galactose medium (n = 6).
(K) Tricarboxylic acid (TCA) cycle intermediates in MOTS-c-ST cells (n = 5).
(L) Acylcarnitine shuttle levels, (M) essential fatty acid levels, and (N) the b-oxidation intermediate myristoyl-CoA levels in MOTS-c-ST cells (n = 5). Data shown as
mean ± SEM. Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S3 and S4 for data on exogenous MOTS-c treatment, null MOTS-c mutants,
non-specific scrambled MOTS-c peptide, and the role of SIRT1 in mediating the glycolytic effects of MOTS-c.of AMPK for the glycolytic effects of MOTS-c. We used siRNA to
knock down AMPKa2 or AMPKa1/2 (Figure S3I) as well as the
AMPK inhibitor compound C in MOTS-c-ST cells. Knockdown
of AMPKa2 alone and AMPKa1/2 showed a 16% and 30%
decrease in glucose-stimulated glycolytic rate, respectively (Fig-
ures 4E, 4F, and 4H), and the inhibition of AMPK by compound C
led to a 40% decrease (Figures 4G and 4H) compared to their
controls. This suggests that AMPK activation plays a partial
role in mediating the actions of MOTS-c. Furthermore, because
of the high levels of NAD+ (Figures 3D and S2C) and the fact that
SIRT1 has an essential role in resveratrol-dependent AMPK acti-
vation (Price et al., 2012), we tested the possible role of SIRT1 in
mediating the glycolytic actions of MOTS-c. Again, we used448 Cell Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc.siRNA to knock down SIRT1 (Figure S3J) as well as the SIRT1 in-
hibitor EX527 (Price et al., 2012) in MOTS-c-ST cells. Knock-
down of SIRT1 led to a 40% decrease in glucose-stimulated
glycolytic rate, and the inhibition of SIRT1 by EX527 led to a
45% decrease (Figures S3K–S3M) in MOTS-c-expressing cells
compared to their controls, suggesting that SIRT1 is partially
necessary for some MOTS-c actions.
Consistent with the ‘‘Crabtree effect,’’ a phenomenon whereby
cells exhibit suppressed respiration in response to high glucose
uptake (Ibsen, 1961), MOTS-c-ST cells and HEK293 cells treated
with MOTS-c showed the characteristic increased glucose
uptake coupled with reduced basal oxygen consumption rate
(OCR). Remarkably, co-treatment with folic acid fully reversed
this effect in both cellular model systems (Figures 4I and S4A).
Transient overexpression of multiple MOTS-c clones in HEK293
cells grown in completemedia also decreased OCR (Figure S4B).
Also, the scrambled MOTS-c peptide (M3S1) did not show
decreased OCR (Figure S3H). To test whether MOTS-c targets
mitochondrial metabolismper se,MOTS-c-ST cells were cultured
in medium with either glucose or galactose as the main carbon
source. In mammalian cells, galactose is largely metabolized by
the mitochondria (Marroquin et al., 2007). MOTS-c reduced
cellular proliferation under conditions of abundant glucose, but
failed to affect cells cultured in galactose medium (Figure 4J).
Reduced oxidative capacity was associated with tricarboxylic
acid (TCA) cycle dysregulation in MOTS-c-ST cells and in
HEK293 cells treated with exogenous MOTS-c (Figures 4K and
S4C). These data suggest that MOTS-c-induced respiratory sup-
pression is likely secondary to increased glucose uptake.
MOTS-c Coordinates Cellular Glucose, Mitochondrial,
and Fatty Acid Metabolism
As the AICAR-AMPK pathway increases lipid metabolism as dis-
cussed above, we assessed the effects of MOTS-c on fatty acid
metabolism.MOTS-c-ST cells exhibited higher levels of carnitine
shuttles (Figure 4L), reduced levels of essential fatty acids (Fig-
ure 4M), and increased levels of the b-oxidation intermediate
myristoyl-CoA compared with control cells (Figure 4N). These
findings were also observed, but to a lesser extent, in cells
treated with exogenous MOTS-c (Figures S4D–S4F). Further-
more, other long-chain fatty acids were significantly reduced,
supporting increased fatty acid utilization (Figures S4G and
S4H). Notably, b-oxidation itself is not an aerobic reaction, and
increased fatty acid oxidation can occur under reduced respira-
tion by AICAR (Spangenburg et al., 2013) andmetformin (Martin-
Montalvo et al., 2013).
To test the effect of MOTS-c on whole-body metabolism,
outbred CD-1 male mice fed a normal diet were treated acutely
with MOTS-c (5 mg/kg/day; BID, 4 days) or vehicle control.
Modest reductions in body weight, food intake, and blood
glucose levels were observed in MOTS-c-treated mice (Figures
S5A–S5C). Basal levels of circulating IL-6 and TNFa (Figure S5D),
implicated in the pathogenesis of obesity and insulin resistance,
were significantly reduced by MOTS-c treatment.
MOTS-c Targets Skeletal Muscle and Regulates Insulin
Sensitivity in Mice
As MOTS-c enhanced cellular glucose flux in vitro, and acute
treatment reduced glucose levels in mice fed a normal diet, we
hypothesized its actions in vivo would be related to glucose
handling and insulin sensitivity. We treated mice with intraperito-
neal injections of MOTS-c for 7 days and then subjected them to
a glucose tolerance test (GTT) and found significantly enhanced
glucose clearance indicative of improved insulin sensitivity (Fig-
ure 5A). Next, we performed hyperinsulinemic-euglycemic clamp
studies to quantify the effects of a 7-day MOTS-c treatment on
whole-body insulin sensitivity independent of changes in body
weight that occur with extended treatment durations (Figures
5B–5D; Table S3). MOTS-c improved whole-body insulin sensi-
tivity as reflected by an30% increase in the exogenous glucose
infusion rate (GIR) required to maintain euglycemia during insulin
stimulation (Figure 5B). Insulin promotes glucose disposal intoCeperipheral tissues and suppresses hepatic glucose production
(HGP) to maintain homeostasis during periods of increased
glucose availability (Kahn, 1994). Tritiated glucose was infused
during the clamp to determine the tissue specificity of MOTS-c
action on insulin sensitivity. We observed thatMOTS-c treatment
significantly enhanced the insulin-stimulated glucose disposal
rate (IS-GDR) (Figure 5C), indicative of enhanced skeletal muscle
insulin sensitivity, but the rate of HGP was comparable between
the groups (Figure 5D). The insulin-stimulated skeletal muscles
were collected at the end of the hyperinsulinemic-euglycemic
clamp. MOTS-c-treated mice showed enhanced ability of in-
fused insulin to activate skeletal muscle Akt, concurrent with
increased detection of MOTS-c (Figure 5E). Considering that
70%–85% of insulin-stimulated glucose disposal is into skeletal
muscle, MOTS-c actions to enhance insulin sensitivity and
glucose homeostasis are likely mediated in this tissue. Because
MOTS-c levels in skeletal muscle (Figure 5F) and in circulation
(Figure 5G) decline concomitantlywith the development of insulin
resistance during aging in mice, we tested if MOTS-c could
reverse age-dependent impairments in insulin action by mea-
suring insulin-stimulated glucose (2-deoxyglucose) uptake
into soleus muscles of middle-aged (12 months) and young
(3 months) male C57BL/6 mice. Reduced insulin sensitivity be-
comes apparent around 1 year of age in C57BL/6 mice (Pearson
et al., 2008). Muscles from older (12 months) mice were more
insulin resistant than younger (3 months) mice, but 7 days of
MOTS-c treatment restored sensitivity in the old mice to levels
comparable to young animals (Figure 5H).
To examine the glycolytic effects of MOTS-c on muscle
in vitro, we generated L6 rat myocytes that stably overexpress
MOTS-c (L6-MOTS-c-ST). Following differentiation to mature
myotubes, we measured glucose levels in the media (steady-
state) and glucose-stimulated and maximum glycolytic capacity
(flux). Similar to the MOTS-c-ST (HEK293) cells, L6-MOTS-c-ST
cells showed accelerated media glucose clearance (Figure 5I)
and enhanced glucose-stimulated and maximum glycolytic
rate (Figures 5J and 5K).
MOTS-c Treatment Prevents High-Fat-Diet-Induced
Obesity and Insulin Resistance in Mice
Given the role of MOTS-c in enhancing insulin sensitivity and
glucose homeostasis, we next tested the effects of MOTS-c
(0.5 mg/kg/day; IP) on outbred CD-1 mice fed a high-fat diet
(HFD; 60% by calories). Although MOTS-c treatment had no ef-
fect on body weight in mice fed a normal diet, it remarkably pre-
vented obesitywhen administrated tomice fed aHFD (Figure 6A).
This difference in body weight was not attributed to food intake,
as caloric intake was identical between the groups (Figures 6B
and 6C). Additionally, MOTS-c treatment prevented HFD-
induced hyperinsulinemia, indicating improved glucose homeo-
stasis (Figures 6D and 6E). Hepatic lipid accumulation was
dramatically reduced in HFD-fedmice treated withMOTS-c (Fig-
ure 6F). Notably, MOTS-c promoted AMPK activation and
GLUT4 expression in the skeletal muscles of HFD-fed mice (Fig-
ure 6G). This corroborates the in vitro actions of MOTS-c on
AMPK activation and GLUT4 expression and also further sup-
ports the skeletal muscle as a major target organ. Mice fed a
HFD and treated with MOTS-c (0.5 mg/kg/day) for 3 weeks
showed increased respiratory exchange ratio (RER; CO2ll Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc. 449
Figure 5. MOTS-c Targets Skeletal Muscle and Regulates Insulin Sensitivity in Mice
(A) Intraperitoneal glucose tolerance test (1 g/kg glucose) in male C57BL/6 mice after MOTS-c treatment (5 mg/kg/day; IP) for 7 days (n = 7).
(B–E) Euglycemic-hyperglycemic clamps on C57BL/6 mice fed a high-fat diet (60% by calories) and treated with MOTS-c (5 mg/kg/day; IP) for 7 days (n = 6–8).
(B) Glucose infusion rate (GIR), reflecting whole-body insulin sensitivity.
(C) Insulin-stimulated glucose disposal rate (IS-GDR), primarily reflecting skeletal muscle insulin sensitivity.
(D) Hepatic glucose production (HGP).
(E) Akt activation (assessed by phosphorylation at Ser473) andMOTS-c levels were detected in the insulin-stimulated skeletal muscles obtained at the end of the
hyperinsulinemic-euglycemic clamp.
(F and G) MOTS-c levels in young (4 months) and aged (32 months) mice (n = 3–4) decline in (F) skeletal muscle and (G) circulation (serum).
(H) Insulin-stimulated (60 mU/ml) 2-deoxyglucose uptake into soleusmuscles of young (3months) andmiddle-aged (12months) male C57BL/6mice afterMOTS-c
treatment (5 mg/kg/day; IP) for 7 days (n = 6).
(I–K) Differentiated mature rat L6 myotubes that stably overexpress MOTS-c (L6-MOTS-c-ST) show (I) accelerated media glucose clearance, (J) enhanced
glucose-stimulated glycolytic response, and (K) maximum glycolytic capacity estimated by oligomycin treatment. Data shown as mean ± SEM. Student’s t test.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Table S3.exhaled/O2 inhaled) (Figure 6H), reflecting increased glucose
utilization. Notably, MOTS-c-treated mice also generated signif-
icantly more heat that may, in part, account for the increased
energy expenditure (Figure 6I). Total activity was comparable be-
tween the two groups (Figure S6). MOTS-c was also able to pre-
vent HFD-induced obesity and hyperinsulinemia independent of
caloric intake in C57BL/6 mice (Figure S7). These studies sug-
gest that MOTS-c prevents HFD-induced obesity by increasing
energy expenditure, including heat production, and improving
glucose utilization and insulin sensitivity. Reduced fat accumula-
tion may be a result of robust carbohydrate usage that reduces
fatty acid synthesis, but the possible involvement of increased
fatty acid oxidation, as observed in vitro, would need detailed ex-
amination before being ruled out.
DISCUSSION
Novel Peptides Derived from Mitochondrial sORFs
as Signaling Molecules
Our understanding of the molecular mechanisms involved in the
communication signals from the mitochondria of particular cells450 Cell Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc.to the rest of those cells and to distant organs is rapidly evolving.
Signals that are sent from the mitochondria to the cell are largely
categorized as mitochondrial retrograde signals and have been
thought to consist of nuclear-encoded proteins that reside in
mitochondria, secondary and transient metabolites, and frag-
ments of damagedmtDNA. Notably, in the nematodeC. elegans,
a stress-induced tissue-specific signal originating from mito-
chondria has been shown to communicate with distant organs
and extend lifespan; the exact identity of this signal, termed ‘‘mi-
tokine,’’ is unknown and currently being investigated (Durieux
et al., 2011; Woo and Shadel, 2011). The demonstration of
MOTS-c as a peptide encoded as a sORF in the mtDNA that is
metabolically and developmentally regulated, which has endo-
crine-like effects on muscle metabolism, insulin sensitivity, and
weight regulation, establishes its role as amember of a new class
of mitochondrial signals which can be called MDPs (Lee et al.,
2013). The MDP humanin similarly acts in a systemic fashion to
protect neuronal and vascular systems from disease processes
and toxic insults (Cohen, 2014; Lee et al., 2013).
Technological advances have unveiled previously unknown
properties of mitochondrial genetics that suggest the existence
Figure 6. MOTS-c Treatment Prevents High-Fat-Diet-Induced Obesity and Insulin Resistance in Mice
(A–G) Male CD-1 mice (8 weeks old) fed a high-fat diet (HFD, 60% by calories) or matched control diet (n = 10) treated with MOTS-c daily (0.5 mg/kg/day; IP) for
8 weeks. (A) body weight, (B) food intake, (C) caloric intake, (D) glucose levels, (E) insulin levels determined at the time of euthanasia, (F) liver H&E staining, and (G)
AMPK phosphorylation (Thr172) and GLUT4 levels in the skeletal muscles of HFD-fed mice treated with MOTS-c or vehicle control.
(H and I) Respiratory exchange ratio (RER) and body heat production values of 8-week-old male CD-1 mice fed a HFD (60% by calories) or matched control diet
treated with MOTS-c daily (0.5 mg/kg/day; IP) for 3 weeks (n = 6). Data shown as mean ± SEM.
(A, H, and I) Repeated-measures two-way ANOVA and (B–E) Student’s t test. **p < 0.01, ***p < 0.001. See also Figure S6 for total activity and Figure S7 for similar
data in C57BL/6 mice.of sORFs in the mtDNA (Mercer et al., 2011). MOTS-c may be a
product of adaptation for effective bilateral communication be-
tween mitochondria in energetically sensitive tissues and cells
of distant organs such as skeletal muscle. We provide here
experimental evidence that MOTS-c, like humanin, is a mito-
chondrial signaling peptide encoded within the mtDNA that reg-
ulates global physiology (Lee et al., 2013).
Regulation of the Folate-AICAR-AMPK Pathway
The unique involvement of the interplay between the folate cycle,
AICAR, and AMPK signaling in MOTS-c action (Figure 7) pro-
vides an interesting opportunity to expand our understanding
of the role of mitochondria in regulating glucose homeostasis.
Interestingly, MOTS-c shares many effects with the antifolate
drug methotrexate: they both (1) target the folate cycle, (2) lead
to the depletion of intracellular 5Me-THF, (3) increase levels of
AICAR (Chan and Cronstein, 2010), (4) activate AMPK (O’NeillCeand Hardie, 2013) in the presence of ATP accumulation most
likely resulting from increased glucose uptake (Diamanti-Kan-
darakis et al., 2010), and (5) decrease mitochondrial respiration
(Sauter et al., 2003). Notably, methotrexate was initially devel-
oped to treat malignancy, but is currently widely used as an
anti-inflammatory drug in rheumatic arthritis (Tennstedt et al.,
2012). Because we observed reduced inflammatory markers in
the microarray and following acute treatment in mice, future di-
rections of MOTS-c investigation should involve its anti-inflam-
matory roles.
Mitochondrial Regulation of Energy Metabolism and
Insulin Sensitivity
Mitochondria are thought to sense the cellular energetic status
and are well recognized to modulate carbohydrate metabolism
through incompletely characterized mechanisms (Woo and
Shadel, 2011). We propose MOTS-c as a novel key endocrinell Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc. 451
Figure 7. MOTS-c: Mitochondrial-Encoded
Regulator of Metabolic Homeostasis
Proposed model of MOTS-c as a mitochondrial
signaling peptide encoded in the mtDNA that reg-
ulates metabolic homeostasis. MOTS-c targets
the skeletal muscle and acts on the folate cycle
(one carbon pool) and inhibits the directly tethered
de novo purine biosynthesis pathway. This leads to
the accumulation of the de novo purine synthesis
intermediate AICAR that is also a potent activator
of the metabolic regulator AMPK, thus partially
mediating the metabolic effects of MOTS-c.signal that originates from mitochondria and systemically regu-
lates in vivo glucose metabolism and muscle insulin action.
MOTS-c also shares some physiological similarities to the first-
line diabetes drug metformin in terms of regulating glucose
utilization, mitochondrial and fatty acid metabolism, and body
weight (Ferguson et al., 2007), which is thought to occur by tar-
geting the folate cycle (Cabreiro et al., 2013; Corominas-Faja
et al., 2012) and signaling via cAMP (Miller et al., 2013) and
AMPK (Shaw, 2013).
One key difference between the actions of metformin and
MOTS-c is that MOTS-c appears to directly target skeletal mus-
cle as the key site of its activity, while metformin is thought to act
primarily on the liver (Diamanti-Kandarakis et al., 2010). Interest-
ingly, the mitochondrial peptide humanin has been shown to
regulate carbohydrate metabolism primarily by acting on hypo-
thalamic and islet cells (Kuliawat et al., 2013; Muzumdar et al.,
2009); this suggests a highly regulated, tissue- and context-spe-
cific targeted MDP effect on whole-body metabolism.
Implications for Metabolic Diseases of Aging
Age-dependent accumulation of mtDNA mutations and conse-
quent metabolic dysfunction are strongly implicated in aging
(Bratic and Larsson, 2013;Wallace, 2011).We hypothesize these
mitochondrial genetic alterations may underlie the age-depen-
dent decline of MOTS-c and humanin levels (Muzumdar et al.,
2009), thus adding another layer of mitochondrial contribution
to aging via the emerging biology of MDPs. Thus, age-related
mtDNA dysfunction could result in both a direct decline in mito-
chondrial function as well as progressive loss of MDP expression
that will diminish their functions as regulatory peptides.
As aging is associated with worsening of mitochondrial func-
tion concomitantly with the development of aging-related dis-
eases such as diabetes and metabolic syndrome, and since
the tissue and circulating levels of humanin and MOTS-c fall
with age, it is compelling to hypothesize that declining MDP
levels are also related to age-related metabolic deterioration.452 Cell Metabolism 21, 443–454, March 3, 2015 ª2015 Elsevier Inc.The profound systemic effects of the
administration of MOTS-c as a daily injec-
tion in aged mice suggest that derivatives
of this molecule might be useful in amelio-
rating the abnormal metabolism associ-
ated with aging in humans.
Finally, the recognition of themitochon-
drial-encoded peptides MOTS-c and hu-
manin suggest the existence of additional
functional sORFs in the mitochondrialgenome and repositions the mitochondria from an ‘‘end-func-
tion’’ organelle to an active regulator of biological processes
such as metabolism and weight homeostasis.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293 and HeLa cells were routinely cultured in DMEM, and L6 myoblasts
were cultured in minimum essential media (MEM) supplemented with 10%
fetal bovine serum (FBS) at 37C with 5% CO2. r0 cells, which are devoid of
mtDNA, were generated by culturing HeLa cells in low doses of ethidium bro-
mide (EtBr; 100 ng/ml) as described before (Hashiguchi and Zhang-Akiyama,
2009). MOTS-c-ST and L6-MOTS-c-ST cells are HEK293 and L6 cells, respec-
tively, stably overexpressing MOTS-c, and were generated by transfecting
MOTS-c expression clone (described below) followed by selection in and
maintenance in G418 (500 mM; Sigma) in DMEM or MEM with 10% FBS. The
control cells for MOTS-c-ST and L6-MOTS-c-ST cells were HEK293 or L6
cells, respectively, stably transfected with empty vector (EV) with the same se-
lection and maintenance method. L6 myoblasts were differentiated to mature
myotubes by culturing in MEM 2% media, once 80%–90% confluence was
reached, for 8–10 days (media replaced every 2–3 days).
Mice Care
All animal work was performed in accordance with the University of Southern
California and University of California, Los Angeles Institutional Animal Care
andUseCommittee. MOTS-c (GenScript) was injected daily via intraperitoneal
injections in all in vivo experiments. CD-1 (ICR) mice (8 weeks old) were pur-
chased fromHarlan. C57BL/6mice were purchased from Jackson Laboratory.
Mice were fed a HFD (60% by calories) and matching control diet purchased
from Research Diets (Cat# D12492 and D12450J, respectively) for 8 weeks.
Pellets were replaced twice weekly, and body weight and food consumption
were recorded daily (n = 10).
Microarray Analysis
RNA was isolated using the RNeasy kit (QIAGEN) and then hybridized to BD-
103-0603 Illumina BeadChips. Raw data were subjected to Z normalization, as
previously described (Cheadle et al., 2003). PCA, performed on the normalized
Z scores of all of the detectable probes in the samples, was performed by us-
ing the DIANE 6.0 software: http://www.grc.nia.nih.gov/branches/rrb/dna/
diane_software.pdf. Significant genes were selected by the Z test < 0.05,
false-discovery rate < 0.30, as well as Z ratio > 1.5 in both directions and
ANOVA p value < 0.05. PAGE was analyzed as previously described (Kim and
Volsky, 2005). Gene regulatory network and canonic pathway analysis was
performed using Ingenuity Pathways Analysis (Ingenuity Systems) (n = 6).
Oxygen Consumption and ECAR
Real-time OCRs were measured using XF24/96 Extracellular Flux Analyzer
(Seahorse Bioscience). ATP turnover and maximum respiratory capacity
were estimated by challenging cells with oligomycin and FCCP (carbonyl cya-
nide 4-[trifluoromethoxy]phenylhydrazone) or DNP (2,4-dinitrophenol). Glyco-
lytic rate was determined using ECAR and individually reported relative to
basal level in percentage. Cells were stimulated with glucose to determine
active glycolytic rate, with oligomycin to determine maximum glycolytic ca-
pacity, and with 2-DG to determine glycolytic capacity. All readings were
normalized to total DNA content.
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